Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
- None.
- None.
HOLON,
"We are delighted to be selected to give two oral presentations at the upcoming Keystone Symposium on Cancer Immunotherapy this year," said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen. "We believe our selection to present at a Keystone Symposium reflects the significant discovery, research and development taking place at Compugen as we are working to advance our vision to transform patient lives by developing first-in class therapeutics based on our computational target discovery platform."
Presentation & poster details | |
Oral presentation date: | Tuesday, March 19, 2024 |
Session title: | Novel insights into T Cell Biology |
Lead author and presenter: | Dr. Assaf Menachem, Ph.D., Compugen |
Presentation & poster title: | Unleashing Natural IL-18 Activity Using an Anti-IL-18BP Blocker Antibody Induces Potent Immune |
Poster date: | Tuesday, March 19, 2024 |
Poster number: | Poster #2042 |
Oral presentation date: | Tuesday, March 19, 2024 |
Oral session title: | Progress in Drugging the TIGIT and VISTA Pathways |
Lead author and presenter: | Dr. Zoya Alteber, Ph.D., Compugen |
Presentation & poster title: | PVRIG is Uniquely Expressed in Tumor Dendritic Cell-rich Niches on Stem-like Memory T Cells and |
Poster date: | Monday, March 18, 2024 |
Poster number: | Poster #1001 |
The abstracts are available on the publication section of Compugen's website www.cgen.com.
The presentations and posters will be made available on www.cgen.com, on the day of presentation.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, Compugen's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, in IND enabling studies is COM503, which is licensed to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-selected-for-two-oral-presentations-at-the-keystone-symposium-on-cancer-immunotherapy-302085114.html
SOURCE Compugen Ltd.
FAQ
What event has Compugen been selected to give two oral presentations at?
What is the focus of the presentations at the symposium?
When and where is the Keystone Symposium on Cancer Immunotherapy taking place?
Who is the lead author and presenter for the presentation on Unleashing Natural IL-18 Activity?
What is the title of the presentation on Unleashing Natural IL-18 Activity?
